IVI Report Examines Imbalances in Health Care Effectiveness Analyses

2018-04-17T15:06:48+00:00 February 21st, 2018|IVI News, Research|

A new Innovation and Value Initiative (IVI) report found that cost-effectiveness analyses (CEAs) are disproportionately conducted on pharmaceutical interventions compared to other health care treatments. Learn more about what causes this and the potential policy solutions to achieve better overall balance of CEAs across health care interventions.

Read more about the project and results here.